Physician profile
Carmen Stelea
NPI 1841440393
$970.04
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $43.57 · 2021: $371 · 2022: $83.88 · 2024: $22.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.92 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $90.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $71.29 | 2019-2021 | |
| Amarin Pharma, INC. | $67.96 | 2019-2021 | |
| Lilly USA, LLC | $59.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.77 | 2019-2021 | |
| Amgen INC. | $50.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.44 | 2019-2022 | |
| Allergan, INC. | $46.70 | 2019 | |
| Pfizer INC. | $43.06 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $41.15 | 2019 | |
| Exeltis, USA INC. | $41.08 | 2021 | |
| Daiichi Sankyo INC. | $35.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.62 | 2021 | |
| Almatica Pharma LLC | $28.90 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.66 | 2022 | |
| Medtronic, INC. | $23.96 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.38 | 2019 | |
| Genentech USA, INC. | $18.82 | 2020 | |
| Therapeuticsmd, INC. | $18.52 | 2019 | |
| Myovant Sciences INC. | $16.52 | 2022 | |
| Welch Allyn | $15.42 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.93 | 2019 | |
| Merck Sharp & Dohme LLC | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Stelea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.